AB
AEON BiopharmaClinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a biosimilar to Botox, for therapeutic indications like cervical dystonia and chronic migraine.
1 Pulse story
AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
AEON BiopharmaAttovia Therapeutics
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
AEON BiopharmaAttovia Therapeutics
Biotech
Sector
Biotech
2013
Founded
2023
Irvine, California
HQ
San Carlos, CA
Public (AEON)
Status
Public (ATTO)
AEON Biopharma investors
No investors on record.
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Data from Value Add Pulse coverage and company research — see the full threads for AEON Biopharma and Attovia Therapeutics.